RE: Uncanny17 Jun 2019 00:05
Quite true Drac, but VAL are commercialising at P2, so 401 going to P3 and it sounds like a few deals all done with a US and Euro Pharma and 201 completes P1/2 this month so, maybe they could go straight to P3, so l am hoping to be pleasantly surprised!
The point being that in the last 5 years they could have never have commercialised as they weren’t ready, but now they are. Also if price sensitive news is due soon, then they will be in a closed period.
I also think that with GM’s experience et al, they know that the dilution to get to P2 is high so why not wait until nearer to commercialisation? Did’t they all invest significant sums at the incorporation of the company which has bern diluted just like many here?
I can see that if good news on 201 / 401 or both that we may see director share option RNS’s shortly.
AIMHO.